IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Pembrolizumab for Newly Diagnosed Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
- Status
- COMPLETED
- Phase
- PHASE2
Pan Tumor Rollover Study
- Status
- RECRUITING
- Phase
- PHASE2
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
- Status
- COMPLETED
- Phase
- PHASE3
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
- Status
- TERMINATED
- Phase
- PHASE1
Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
- Status
- WITHDRAWN
- Phase
- PHASE4
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
- Status
- COMPLETED
- Phase
- PHASE3
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
- Status
- WITHDRAWN
- Phase
- PHASE3
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
- Status
- COMPLETED
- Phase
- PHASE2
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1